MC
ASBPW

Meteora Capital’s Aspire Biopharma Warrant ASBPW Stock Holding History

Meteora Capital’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,000
Closed -$888 – 193
2024
Q3 		$888 Sell
21,000
-4,000
-16% -$190 ﹤0.01% 198
2024
Q2 		$936 Hold
25,000
– – ﹤0.01% 241
2024
Q1 		$753 Hold
25,000
– – ﹤0.01% 263
2023
Q4 		$1.5K Hold
25,000
– – ﹤0.01% 281
2023
Q3 		$1.27K Buy
+25,000
New +$2.02K ﹤0.01% 337

Other funds holding ASBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Meteora Capital's ASBPW Position: Q4 2024 in Review

Meteora Capital sold out of Aspire Biopharma Warrant (ASBPW) in Q4 2024, closing a stake of 21,000 shares — an estimated $888 sold.

Meteora Capital first reported a position in ASBPW in Q3 2023 and held it in 5 quarters. The position peaked at $1.5K in Q4 2023. 26 funds tracked by Wall St. Rank hold ASBPW as of Q4 2024.

  • Meteora Capital reported no remaining Aspire Biopharma Warrant position as of Q4 2024 after selling out during the quarter.
  • Meteora Capital sold 21,000 Aspire Biopharma Warrant shares in Q4 2024, an estimated $888.
  • Meteora Capital first reported a position in Aspire Biopharma Warrant in Q3 2023 and held it in 5 quarters.
  • Meteora Capital's Aspire Biopharma Warrant position peaked at $1.5K in Q4 2023.
  • 26 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q4 2024.

Based on Meteora Capital's 13F filing for Q4 2024, filed 14 Feb 2025.